HLA-A

HLA-A Full Name

major histocompatibility complex, class I, A

HLA-A Introduction

HLA-A (major histocompatibility complex, class I, A) is a central antigen-presenting molecule that determines how effectively cytotoxic CD8⁺ T cells recognize infected or malignant cells, making it a foundational target in modern cancer immunology and T-cell–based therapies. For researchers and developers working on TCR-T or cancer vaccines, a recurring challenge is HLA restriction: therapeutic efficacy is tightly linked to specific HLA-A alleles within patient populations. High-frequency alleles such as HLA-A11:01 in Asian populations and HLA-A02:01 globally have therefore become strategic focal points. Recent studies identifying novel HLA-A–restricted viral and tumor epitopes, including HPV16 E6/E7 and hepatocellular carcinoma–associated antigens, directly address the unmet need for actionable, population-relevant immune targets, enabling more precise and translatable T-cell therapies.

Functionally, HLA-A presents endogenously processed peptides in complex with β2-microglobulin (B2M) to CD8⁺ T cells, acting as a gatekeeper of immune surveillance. However, tumors frequently exploit this pathway to evade immunity. Loss or downregulation of HLA-A or B2M expression is now recognized as a common and clinically relevant immune escape mechanism, particularly in advanced and metastatic cancers. This creates a major pain point for immunotherapy: patients may fail to respond despite having tumor-reactive T cells or receiving checkpoint inhibitors. Importantly, emerging evidence shows that HLA-A/B2M expression is not static; dynamic restoration during treatment has been associated with improved clinical responses, positioning HLA-A not only as a functional immune molecule but also as a potential on-treatment biomarker for monitoring immunotherapy effectiveness.

From a disease and translational perspective, differential expression and prognostic value of HLA-A compared with other class I molecules such as HLA-B and HLA-C further highlight its unique relevance. In colorectal cancer and other solid tumors, HLA-A expression has shown a stronger association with patient survival, suggesting it may be a more sensitive indicator of immune competence within the tumor microenvironment. At the same time, allele-specific epitope discovery—such as HLA-A*02:01-restricted antigens in hepatocellular carcinoma—directly fuels the development of next-generation T-cell therapies and therapeutic vaccines. Together, these findings position HLA-A at the intersection of immune escape, biomarker discovery, and precision immunotherapy, addressing critical bottlenecks faced by researchers, clinicians, and biopharma developers aiming to improve patient selection and therapeutic outcomes.

Alternate Names for HLA-A

HLA-A; major histocompatibility complex, class I, A; HLAA; HLA class I histocompatibility antigen, A-1 alpha chain; antigen presenting molecule; leukocyte antigen class I-A; MHC class I antigen HLA-A heavy chain;

• 1.Thakur A, et al.; Inhibition of Glioma Cells' Proliferation by Doxorubicin-Loaded Exosomes via Microfluidics. Int J Nanomedicine. 2020, 15:8331-8343.
  2.Xiong C, et al.; Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy. J Immunother Cancer. 2022, 10(9):e004790.